Evaluation in nonhuman primates of vaccines against Ebola virus

Thomas Geisbert, Peter Pushko, Kevin Anderson, Jonathan Smith, Kelly J. Davis, Peter B. Jahrling

Research output: Contribution to journalArticle

195 Scopus citations

Abstract

Ebola virus (EBOV) causes acute hemorrhagic fever that is fatal in up to 90% of cases in both humans and nonhuman primates. No vaccines or treatments are available for human use. We evaluated the effects in nonhuman primates of vaccine strategies that had protected mice or guinea pigs from lethal EBOV infection. The following immunogens were used: RNA replicon particles derived from an attenuated strain of Venezuelan equine encephalitis virus (VEEV) expressing EBOV glycoprotein and nucleoprotein; recombinant Vaccinia virus expressing EBOV glycoprotein; liposomes containing lipid A and inactivated EBOV; and a concentrated, inactivated whole-virion preparation. None of these strategies successfully protected nonhuman primates from robust challenge with EBOV. The disease observed in primates differed from that in rodents, suggesting that rodent models of EBOV may not predict the efficacy of candidate vaccines in primates and that protection of primates may require different mechanisms.

Original languageEnglish (US)
Pages (from-to)503-507
Number of pages5
JournalEmerging Infectious Diseases
Volume8
Issue number5
StatePublished - 2002
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Geisbert, T., Pushko, P., Anderson, K., Smith, J., Davis, K. J., & Jahrling, P. B. (2002). Evaluation in nonhuman primates of vaccines against Ebola virus. Emerging Infectious Diseases, 8(5), 503-507.